NCT05246813 Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)
| NCT ID | NCT05246813 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imelda Hospital, Bonheiden |
| Condition | Osteoporosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 24 participants |
| Start Date | 2022-02-11 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 24 participants in total. It began in 2022-02-11 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations. Combined single-cell transcriptomics and mutation-specific single-cell genotyping (biotin-PCR using mutation-targeted primers followed by sequencing) will subsequently be performed. The gene expression profile of wildtype and mutant hematopoietic stem cells will be compared, performing both broad gene set enrichment analysis and targeted analysis of metabolic pathways.
Eligibility Criteria
Inclusion Criteria: * Age 65 years and older Exclusion Criteria: * known haematological condition (myelodysplasia, leukemia, cancer) * inability to provide written informed consent
Contact & Investigator
Nick Van Gastel, PhD
PRINCIPAL INVESTIGATOR
de Duve Institute
Frequently Asked Questions
Who can join the NCT05246813 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying Osteoporosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05246813 currently recruiting?
Yes, NCT05246813 is actively recruiting participants. Contact the research team at michael.laurent@imelda.be for enrollment information.
Where is the NCT05246813 trial being conducted?
This trial is being conducted at Bonheiden, Belgium.
Who is sponsoring the NCT05246813 clinical trial?
NCT05246813 is sponsored by Imelda Hospital, Bonheiden. The principal investigator is Nick Van Gastel, PhD at de Duve Institute. The trial plans to enroll 24 participants.